Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 27:11:682325.
doi: 10.3389/fonc.2021.682325. eCollection 2021.

The Role of Neoantigens in Cancer Immunotherapy

Yueting Zhu  1 , Jiyan Liu  1   2
Affiliations
Review

The Role of Neoantigens in Cancer Immunotherapy

Yueting Zhu et al. Front Oncol. .

Abstract

Somatic mutation-derived neoantigens, expressed only on tumor cells, may elicit antitumor T-cell responses in cancer immunotherapies with minimal immune tolerance. Neoantigens can be identified by multiple bioinformatics technologies, mainly based on whole-exome sequencing. Personalized cancer vaccines and adoptive T cell therapies are two primary treatment modalities targeting neoantigens, and both of them have shown promising therapeutic effects. This review, summarizes the history of neoantigen-related tumor control, introduces recent neoantigen screening and identification methods, and discusses the role of neoantigen in cancer immunotherapies. Moreover, we propose the challenges of targeting neoantigens for cancer treatment.

Keywords: adoptive cell therapy; immunotherapy; neoantigen; personalized treatment; vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. De Mattos-Arruda L, Blanco-Heredia J, Aguilar-Gurrieri C, Carrillo J, Blanco J. New Emerging Targets in Cancer Immunotherapy: The Role of Neoantigens. ESMO Open (2020) 4(Suppl 3):e000684. 10.1136/esmoopen-2020-000684. - DOI - PMC - PubMed
    1. Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. . Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. JAMA Oncol (2018) 4(12):1721–8. 10.1001/jamaoncol.2018.3923 - DOI - PMC - PubMed
    1. Linnemann C, Mezzadra R, Schumacher TN. TCR Repertoires of Intratumoral T-Cell Subsets. Immunol Rev (2014) 257(1):72–82. 10.1111/imr.12140 - DOI - PubMed
    1. De Mattos-Arruda L, Vazquez M, Finotello F, Lepore R, Porta E, Hundal J, et al. . Neoantigen Prediction and Computational Perspectives Towards Clinical Benefit: Recommendations From the ESMO Precision Medicine Working Group. Ann Oncol (2020) 31(8):978–90. 10.1016/j.annonc.2020.05.008 - DOI - PMC - PubMed
    1. Srivastava RM, Purohit TA, Chan TA. Diverse Neoantigens and the Development of Cancer Therapies. Semin Radiat Oncol (2020) 30(2):113–28. 10.1016/j.semradonc.2019.12.001 - DOI - PubMed

LinkOut - more resources